Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases
April 25, 2022 08:30 ET
|
Veru Inc.
MIAMI, April 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that results from the randomized placebo-controlled Phase 2 study of daily, oral...
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
April 11, 2022 06:30 ET
|
Veru Inc.
-- Independent Data Monitoring Committee Unanimously Recommends that Phase 3 Clinical Trial for Sabizabulin for Treatment of Hospitalized COVID-19 Patients at High Risk for ARDS Be Stopped Early Due...
Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference
March 04, 2022 08:30 ET
|
Veru Inc.
MIAMI, March 04, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate...
Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022
March 01, 2022 08:30 ET
|
Veru Inc.
MIAMI, March 01, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate...
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
February 17, 2022 08:30 ET
|
Veru Inc.
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,...
Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
February 14, 2022 08:30 ET
|
Veru Inc.
--Planned Conditional Statistical Power Analysis was Conducted— --Primary Efficacy Study Endpoint Is Proportion of Patients that Die on Study Up to Day 60-- --Global Phase 3 Sabizabulin COVID-19...
Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%
February 09, 2022 06:30 ET
|
Veru Inc.
--FC2 Prescription Business Entering 6th Year of Growth -- --FDA Approves Company’s ENTADFI™, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway-- ...
Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial
February 01, 2022 08:30 ET
|
Veru Inc.
-- Phase 3 ENABLAR-2 Clinical Trial for 2nd Line Treatment of AR+ER+HER2- Metastatic Breast Cancer Expected to Commence During First Quarter of 2022 -- MIAMI, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Veru...
Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
January 31, 2022 08:30 ET
|
Veru Inc.
-- Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitalized Moderate to Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome Being Conducted in US, Mexico,...
Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9th
January 26, 2022 08:30 ET
|
Veru Inc.
MIAMI, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,...